|
⚲
|
| Keyboard |
| Soleus Private Equity GP I LLC | |
|---|---|
| Firm | Soleus Capital Management LP |
| Address | 104 Field Point Road 2nd Floor Greenwich, CT 06830 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Soleus Capital Management LP | |||||
| Soleus BA SPV LLC | 021-340613 | Executive Officer | 8.3 M of 8.3 M |
0.1 M | |
| Soleus BB SPV LLC | 021-340613 | Executive Officer | 8.3 M of 8.3 M |
0.9 M | |
| Soleus Private Equity Fund I LP | 021-321871 | Executive Officer | 85.5 M of 125.0 M |
6.6 M | |
| Soleus BA SPV LLC | 021-382158 | Director | 5.7 M of 5.7 M |
||
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Sell | 16,909 | $16.00 | 270,544 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Buy | 155,000 | $16.00 | 2,480,000 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Conversion | 338,330 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Conversion | 104,608 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2020-05-05 | Option exercise | 31,382 | $8.63 | 270,827 |
|
Lyra Therapeutics Inc LYRA
Series B Convertible Preferred Stock · derivative
|
2020-05-05 | Conversion | 11,666,666 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Common Stock Warrant · derivative
|
2020-05-05 | Option exercise | 31,382 | $0.00 | |
|
Lyra Therapeutics Inc LYRA
Series C Convertible Preferred Stock · derivative
|
2020-05-05 | Conversion | 3,607,224 | $0.00 |